The latest in our well established series, SMi's 'Asthma & COPD' returns to London in March 2017 to reflect on the ongoing issues and latest developments to these two diseases.

This years' event will bring together industry leaders to discuss the latest challenges and changes in the fields of asthma and COPD. We will explore novel approaches to treatment, exploring biomarkers and targeted treatments. We will identify challenges to device development and drug delivery, deepen our understanding of the problems relating to these diseases, and discuss the hot topic of electronic health monitoring.

Asthma and COPD are two of the most common, and deadly, diseases in the UK. Under diagnosis and incorrect medicine use remain the greatest problems to these diseases. However, cutting edge developments in targeted drugs and personalized treatments are currently revolutionising the ways in which industry are addressing asthma and COPD.

Presentations and selected case studies from industry experts on asthma and COPD, cutting edge approaches to treatment, key decision makers in these fields and unique networking opportunities will make this an event a not to miss opportunity.

This year's agenda will focus on the challenges experienced by pharmaceuticals as they work to combat asthma and COPD. There will be a strong development focus, and updates on the innovative strategies currently being implemented to overcome long established hurdles to asthma and COPD.

This year will feature two half day workshops, one covering the new and exciting topic of electronic healthcare, a topic set to become a large part of pharmaceutical data collection and healthcare delivery, the other exploring fresh and innovative approaches to COPD.

9:00 Chairman's Opening Remarks

9:10 EU & UK regulatory consderations for the development of inhaled products

Dr Yang is a Pharmaceutical Assessor at the Medicines and Healthcare Products Regulatory Agency (MHRA) in London. She is responsible for assessing the chemical and pharmaceutical data in relation to abridged applications (national, mutual recognition, decentralised and centralised) and new applications of topical products including inhaled products, dermatological products and endocrine systems. Dr Yang has been involved in the assessment of applications for new inhaled products, including dry powder inhalers and MDI’s, and the provision of Scientific Advices for both national and European centralised procedures. Dr Yang is a UK registered pharmacist and holds a PhD in pharmaceutical science.

• EU and UK regulatory hurdles to developing and registering a generic inhalation product
• Regulations for inhalation drug development, including combination considerations
• Regulatory updates on the device component of a medicinal product
• How does device type affect the development and approval process?

9:50 Overcoming challenges to industry in the device development process

Dr. Stefan Leiner is a pharmacist by training and joined Boehringer Ingelheim in Germany in 1987. After a couple of years in manufacture, galenical and analytical development, he focussed on inhalation forms.

He now holds the title of a “CMC Expert", meaning he is responsible for the scientific standard of the Module 3 of MAAs. He wrote the Quality Overall Summaries for many of Boehringer Ingelheim’s new inhalation developments.

Stefan Leiner represents Boehringer Ingelheim in the International Pharmaceutical Aerosol Consortium - Regulation and Science (IPAC-RS) and was chair of this organization. He participated in the development of the ISO 20072 Standard on "Aerosol Drug Delivery Devices". He is active in the German Pharmacopeia.

• Moving away from generic development
• Taking age group into consideration when developing a device; considerations for paediatric and elderly patients
• Incorporating clinical trials as a key step in obtaining device approval
• USP regulatory update on spacers in new devices

10:30 Morning Coffee

11:00 Maximising the use and impact of inhaled therapies; addressing the true needs of patients and HCPs

Monica Fletcher is Chief Executive of Education for Health. She is also Chair of UK Inhaler Group, Knowledge Exchange Lead for Asthma UK Centre for Applied Research (AUKCAR) and Past Chair of the European Lung Foundation

Monica influences national and international policies through activities including membership of the WHO’s Global Alliance Against Respiratory Disease, European Respiratory Society, American Thoracic Society, European COPD Coalition, and International Primary Care Respiratory Group.

Monica is honoured with an OBE, a Queen’s Nursing Institute Fellowship and a European Respiratory Society Fellowship, joining a group of leaders acknowledged for lifetime excellence and contributions to respiratory medicine.

• How do patients and HCPs describe their inhalers?
• Does colour matter anymore?
• Will technology help or hinder adherence?
• How can we educate patients and HCPs?

11:40 Matching device and treatment to disease stage; considerations for the treatment of asthma

·Challenges to the development of novel inhalers; increased cost of development vs. improved performance and decreased cost to NHS

·Targeting severe exacerbation with novel monoclonal antibodies

oMechanism for targeting and exacerbation reduction

oKnock on effects to NHS and pricing strategies

12:20 Networking Lunch

13:30 Inhaled calcilytics for inflammatory lung disease

Daniela Riccardi , Professor of Physiology and Deputy Head, School of Biosciences, Cardiff University View Bio

Daniela Riccardi obtained her BA in Zoology and MRes in Physiopathological methods from the University of Milan, Italy, where she investigated mechanisms of water transport in mammalian epithelia. Her PhD in Physiology was completed working between the University of Milan and the Harvard Medical School, Boston, USA, under the supervision of Prof. SC Hebert, in the Renal Division of the Brigham and Women's Hospital. Daniela was part of the team that identified the extracellular calcium-sensing receptor, CaR, which is the first G protein-coupled receptor hah has an ion, calcium, as its ligand. She then went on to identify the renal calcium-sensing receptor. Following her work on the CaR, Daniela was awarded the first prize in Excellence in Research from the American Society of Nephrology and National Kidney Foundation, a Research Fellowship from the National Kidney Foundation and The Wellcome Trust Prize for Excellence in Physiology. In 1997, Daniela moved to the UK and established her own research group at Manchester University, remaining there until 2004. In 2004, she moved to the School of Biosciences at Cardiff University where currently she is Professor of Physiology and Deputy Head of the School of Biosciences. Daniela’s research interests centre on how cells sense and respond to perturbations in the extracellular milieu, particularly Ca2+, polycations and nutrients. Daniela’s scientific goals are: 1. to develop CaSR antagonists (calcilytics) as novel therapeutics for inflammatory lung disease, and; 2. to define the role of the CaSR in blood pressure control and in the prevention of vascular calcification.

14:50 Afternoon Tea

15:20 Biologics; targeted treatment to targeted cases

I am currently Principal Scientist and Team Leader in Respiratory, Inflammation and Autoimmunity (RIA) at MedImmune Ltd, Cambridge, UK, having joined 18 years ago when Cambridge Antibody Technology.
My team is currently focussed on investigating novel mechanisms and target generation in the pathogenesis of COPD (chronic obstructive pulmonary disease). We focus on human biology, accessing valuable disease lung samples, and using innovative 3D-culture techniques, imaging and –omics technologies. Along with RIA and Translational Science colleagues at our Gaithersburg site, we address patient stratification in COPD, and we are particularly interested in biomarkers and epidemiology of exacerbations of COPD. I have been involved in multiple drug projects in COPD and inflammatory diseases (such as rheumatologic disease), leading several biologic therapies through to early clinical trials (such as antibodies to interleukin 6, interleukin-1RI, and others). I am an Industrial Lead for the UK Consortium COPD-MAP, and we work directly with Spiromics and COPD-GENE investigators (US consortia), and collaborate extensively with key COPD investigators worldwide.
I have previously worked for Glaxo Group Research (UK), and Roche Biosciences (Palo Alto, Ca, USA), and I achieved my BSc from University of Bristol, and my PhD from University of Leicester, where I studied the signalling and function of muscarinic receptors in smooth muscle.

16:40 Chairman’s Closing Remarks and Close of Day One

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Stephen Beckman has devoted his entire 24-year career to the life sciences industry in a broad range of operational and commercial positions within both regional (US) and global organizations. During his career, Stephen has become an expert in a number of therapeutic areas including respiratory and rare diseases as well as specific subject matter areas in commercial operations, start-up management, strategic planning, business development, product launch, and partnership management. He is currently Head of Global Respiratory and Allergy at Mylan, Inc. In this role he is responsible for the global strategy and implementation of the respiratory and allergy portfolio which is expected to exceed $2 billion by 2018. Previously, Mr Beckman was the President/Director of North America for Pharmaxis, Inc. with responsibility over all business activities for both North and South America. Mr. Beckman lead the efforts for the US approval of Aridol®, a novel new asthma diagnostic and the approval efforts for Bronchitol® for the treatments of cystic fibrosis and bronchiectasis.
Stephen has demonstrated a consistent ability to effectively work within emerging pharmaceutical companies such as Pharmaxis as General Manager of Exaeris, Inc. as well as successful track records in a number of large pharmaceutical concerns as Corporate Vice President of Global Marketing at Altana Pharmaceuticals and Worldwide Director of Pulmonary at SmithKline Beecham Pharmaceuticals (GSK). It has been through these diverse experiences that Mr. Beckman has been able to develop critical skill sets such as entrepreneurial ingenuity, transparent leadership, strategic communication, and critical thinking required to deliver sustainable solutions within the ever-changing landscape of the Pharmaceutical Industry.
The pathway to these positions has been built from a career in sales and product management, licensing, and portfolio development with Astra Zeneca, and Fisons Pharmaceuticals.
Stephen earned his B.S., in business from Syracuse University with an additional concentration in Advertising and Communications. He actively participates in the life sciences community through a number of industry boards, committees and lecturing which include:
• University of Pennsylvania (Wharton) Executive MBA – annual guest lecturer on business strategy and human capital.
• Adjunct lecturer at St. Joseph’s University Pharmaceutical Executive MBA.
• Committee member Genesyn IP Ventures in association with Temple University School of Medicine and health system.

9:10 Integration of innovation and opportunity in COPD

Stephen Beckman has devoted his entire 24-year career to the life sciences industry in a broad range of operational and commercial positions within both regional (US) and global organizations. During his career, Stephen has become an expert in a number of therapeutic areas including respiratory and rare diseases as well as specific subject matter areas in commercial operations, start-up management, strategic planning, business development, product launch, and partnership management. He is currently Head of Global Respiratory and Allergy at Mylan, Inc. In this role he is responsible for the global strategy and implementation of the respiratory and allergy portfolio which is expected to exceed $2 billion by 2018. Previously, Mr Beckman was the President/Director of North America for Pharmaxis, Inc. with responsibility over all business activities for both North and South America. Mr. Beckman lead the efforts for the US approval of Aridol®, a novel new asthma diagnostic and the approval efforts for Bronchitol® for the treatments of cystic fibrosis and bronchiectasis.
Stephen has demonstrated a consistent ability to effectively work within emerging pharmaceutical companies such as Pharmaxis as General Manager of Exaeris, Inc. as well as successful track records in a number of large pharmaceutical concerns as Corporate Vice President of Global Marketing at Altana Pharmaceuticals and Worldwide Director of Pulmonary at SmithKline Beecham Pharmaceuticals (GSK). It has been through these diverse experiences that Mr. Beckman has been able to develop critical skill sets such as entrepreneurial ingenuity, transparent leadership, strategic communication, and critical thinking required to deliver sustainable solutions within the ever-changing landscape of the Pharmaceutical Industry.
The pathway to these positions has been built from a career in sales and product management, licensing, and portfolio development with Astra Zeneca, and Fisons Pharmaceuticals.
Stephen earned his B.S., in business from Syracuse University with an additional concentration in Advertising and Communications. He actively participates in the life sciences community through a number of industry boards, committees and lecturing which include:
• University of Pennsylvania (Wharton) Executive MBA – annual guest lecturer on business strategy and human capital.
• Adjunct lecturer at St. Joseph’s University Pharmaceutical Executive MBA.
• Committee member Genesyn IP Ventures in association with Temple University School of Medicine and health system.

• Innovation serving new ways to treat and manage unique sub populations in COPD
• Impact of RX and GX solutions in COPD and Asthma
• How advanced delivery solutions will impact the market
• Changes in payer and provider care impacts innovation
• What trends will most affect the next ten years in Asthma and COPD

9:50 Early interception of COPD

Christopher Stevenson, Venture Leader, COPD Interception, Janssen

• Focussing on early identification of COPD using targeted biomarkers and identifying related disease pathways
• Impact of early interception to later disease course, progression and treatment strategies
• Integrating novel therapeutics and diagnostics to address patient susceptibility to COPD

10:30 Morning Coffee

11:00 Novel anti-inflammatory approaches in the treatment of COPD

Dr. Neelima Khairatkar-Joshi is a Sr. Vice President & Head, NCE Drug Discovery Research at Glenmark Pharmaceuticals, New Mumbai, India. She has over 24 years of experience in the New Drug Discovery research.

In her current role, she is responsible for driving all preclinical decisions leading to identification of an IND enabling lead candidate in therapy areas of Inflammation, Chronic Pain and Respiratory Disease. During her 16 years career at Glenmark, she has successfully contributed to deliver numerous IND enabling innovative molecules that progressed into clinical trials. Dr. Neelima is an inventor on over 80 published patents (world), has authored over 50 abstracts and 10 peer reviewed publications / book chapters of renowned publishers / journals such as Elsevier, Expert Opinion, Trend and Molecular Medicine. She has presented over 15 invited lectures in key international forums in areas of drug discovery.

Prior to joining Glenmark, Dr Neelima worked on natural product based New Drug Discovery Research at Hoechst Marion Roussel (Now Sanofi Avantis) for about 8 years. She earned her Ph.D. in Molecular Biology, Masters in Microbiology.

Lung inflammation orchestrations in COPD

Past and present approaches to anti-inflammatory screening

Breaking down inflammation; from animals to man to patients; mind the gap

Will novel targets deliver novel therapeutics in COPD

11:40 Phenotyping asthma and COPD disease types

Neil Barnes, Medical Head Global Respiratory Franchise, GSK

• Rethinking diagnosis criteria for asthma and COPD based on genetic phenotyping
• Impacts of phenotyping on treatment type, and individuality of treatment
• Patient stratification using phenotypic patient subsets

12:20 Networking Lunch

13:30 'Real time data collection' - The Salford Lung Study

Dave Leather is a Global Medical Affairs Leader in the Respiratory Franchise at GSK, based at GSK House in London in the UK. He leads the Global Medical Expert team: a team of world renowned Respiratory experts who work for GSK providing internal scientific and clinical expertise to support promoted medicines and those in development. For the last 3 years he led a team responsible for developing phase lll and phase lV trials for respiratory medicines. He also has a leadership role in “real world pragmatic trials” and is the Franchise leader of the internationally recognised Salford Lung Study.
Dave joined GSK in 2000 and has held a variety of posts within the company. Originally a primary care physician in Bolton with an interest in respiratory disease, Dave managed asthma and COPD clinics in a primary care setting and held a post as a clinical assistant in Respiratory Medicine at University Hospital Aintree in Liverpool. He was a GP Course Organiser, a member of the Council of the Royal College of GPs (RCGP), and worked as a media doctor for the BBC and commercial radio.

Adnan Custovic, Clinical Professor of Paediatric Allergy, Imperial College London

• Heterogeneity of asthma now widely accepted
o General consensus: There are different asthma endotypes
o No consensus: What these are and how best to define them
• Major challenge is to bridge the gap between:
o Identifying subtypes of asthma in clinical and general populations
o Understanding their causal mechanisms (both shared and unique)
o Translating this knowledge into biomarkers and strategies to facilitate stratified prevention and management strategies

15:30 Chairman’s Closing Remarks and Close of Day Two

15:40 Afternoon Tea and Networking

FEATURED SPEAKERS

Professor of Physiology and Deputy Head, School of Biosciences, Cardiff University

Daniela Riccardi obtained her BA in Zoology and MRes in Physiopathological methods from the University of Milan, Italy, where she investigated mechanisms of water transport in mammalian epithelia. Her PhD in Physiology was completed working between the University of Milan and the Harvard Medical School, Boston, USA, under the supervision of Prof. SC Hebert, in the Renal Division of the Brigham and Women's Hospital. Daniela was part of the team that identified the extracellular calcium-sensing receptor, CaR, which is the first G protein-coupled receptor hah has an ion, calcium, as its ligand. She then went on to identify the renal calcium-sensing receptor. Following her work on the CaR, Daniela was awarded the first prize in Excellence in Research from the American Society of Nephrology and National Kidney Foundation, a Research Fellowship from the National Kidney Foundation and The Wellcome Trust Prize for Excellence in Physiology. In 1997, Daniela moved to the UK and established her own research group at Manchester University, remaining there until 2004. In 2004, she moved to the School of Biosciences at Cardiff University where currently she is Professor of Physiology and Deputy Head of the School of Biosciences. Daniela’s research interests centre on how cells sense and respond to perturbations in the extracellular milieu, particularly Ca2+, polycations and nutrients. Daniela’s scientific goals are: 1. to develop CaSR antagonists (calcilytics) as novel therapeutics for inflammatory lung disease, and; 2. to define the role of the CaSR in blood pressure control and in the prevention of vascular calcification.

Dave Leather is a Global Medical Affairs Leader in the Respiratory Franchise at GSK, based at GSK House in London in the UK. He leads the Global Medical Expert team: a team of world renowned Respiratory experts who work for GSK providing internal scientific and clinical expertise to support promoted medicines and those in development. For the last 3 years he led a team responsible for developing phase lll and phase lV trials for respiratory medicines. He also has a leadership role in “real world pragmatic trials” and is the Franchise leader of the internationally recognised Salford Lung Study.
Dave joined GSK in 2000 and has held a variety of posts within the company. Originally a primary care physician in Bolton with an interest in respiratory disease, Dave managed asthma and COPD clinics in a primary care setting and held a post as a clinical assistant in Respiratory Medicine at University Hospital Aintree in Liverpool. He was a GP Course Organiser, a member of the Council of the Royal College of GPs (RCGP), and worked as a media doctor for the BBC and commercial radio.

Monica Fletcher is Chief Executive of Education for Health. She is also Chair of UK Inhaler Group, Knowledge Exchange Lead for Asthma UK Centre for Applied Research (AUKCAR) and Past Chair of the European Lung Foundation

Monica influences national and international policies through activities including membership of the WHO’s Global Alliance Against Respiratory Disease, European Respiratory Society, American Thoracic Society, European COPD Coalition, and International Primary Care Respiratory Group.

Monica is honoured with an OBE, a Queen’s Nursing Institute Fellowship and a European Respiratory Society Fellowship, joining a group of leaders acknowledged for lifetime excellence and contributions to respiratory medicine.

Dr Yang is a Pharmaceutical Assessor at the Medicines and Healthcare Products Regulatory Agency (MHRA) in London. She is responsible for assessing the chemical and pharmaceutical data in relation to abridged applications (national, mutual recognition, decentralised and centralised) and new applications of topical products including inhaled products, dermatological products and endocrine systems. Dr Yang has been involved in the assessment of applications for new inhaled products, including dry powder inhalers and MDI’s, and the provision of Scientific Advices for both national and European centralised procedures. Dr Yang is a UK registered pharmacist and holds a PhD in pharmaceutical science.

Dr. Stefan Leiner is a pharmacist by training and joined Boehringer Ingelheim in Germany in 1987. After a couple of years in manufacture, galenical and analytical development, he focussed on inhalation forms.

He now holds the title of a “CMC Expert", meaning he is responsible for the scientific standard of the Module 3 of MAAs. He wrote the Quality Overall Summaries for many of Boehringer Ingelheim’s new inhalation developments.

Stefan Leiner represents Boehringer Ingelheim in the International Pharmaceutical Aerosol Consortium - Regulation and Science (IPAC-RS) and was chair of this organization. He participated in the development of the ISO 20072 Standard on "Aerosol Drug Delivery Devices". He is active in the German Pharmacopeia.

Stephen Beckman has devoted his entire 24-year career to the life sciences industry in a broad range of operational and commercial positions within both regional (US) and global organizations. During his career, Stephen has become an expert in a number of therapeutic areas including respiratory and rare diseases as well as specific subject matter areas in commercial operations, start-up management, strategic planning, business development, product launch, and partnership management. He is currently Head of Global Respiratory and Allergy at Mylan, Inc. In this role he is responsible for the global strategy and implementation of the respiratory and allergy portfolio which is expected to exceed $2 billion by 2018. Previously, Mr Beckman was the President/Director of North America for Pharmaxis, Inc. with responsibility over all business activities for both North and South America. Mr. Beckman lead the efforts for the US approval of Aridol®, a novel new asthma diagnostic and the approval efforts for Bronchitol® for the treatments of cystic fibrosis and bronchiectasis.
Stephen has demonstrated a consistent ability to effectively work within emerging pharmaceutical companies such as Pharmaxis as General Manager of Exaeris, Inc. as well as successful track records in a number of large pharmaceutical concerns as Corporate Vice President of Global Marketing at Altana Pharmaceuticals and Worldwide Director of Pulmonary at SmithKline Beecham Pharmaceuticals (GSK). It has been through these diverse experiences that Mr. Beckman has been able to develop critical skill sets such as entrepreneurial ingenuity, transparent leadership, strategic communication, and critical thinking required to deliver sustainable solutions within the ever-changing landscape of the Pharmaceutical Industry.
The pathway to these positions has been built from a career in sales and product management, licensing, and portfolio development with Astra Zeneca, and Fisons Pharmaceuticals.
Stephen earned his B.S., in business from Syracuse University with an additional concentration in Advertising and Communications. He actively participates in the life sciences community through a number of industry boards, committees and lecturing which include:
• University of Pennsylvania (Wharton) Executive MBA – annual guest lecturer on business strategy and human capital.
• Adjunct lecturer at St. Joseph’s University Pharmaceutical Executive MBA.
• Committee member Genesyn IP Ventures in association with Temple University School of Medicine and health system.

Adnan Custovic

Boris Ferko

Christopher Stevenson

Venture Leader, COPD Interception, Janssen

Daniela Riccardi

Professor of Physiology and Deputy Head, School of Biosciences, Cardiff University

Daniela Riccardi obtained her BA in Zoology and MRes in Physiopathological methods from the University of Milan, Italy, where she investigated mechanisms of water transport in mammalian epithelia. Her PhD in Physiology was completed working between the University of Milan and the Harvard Medical School, Boston, USA, under the supervision of Prof. SC Hebert, in the Renal Division of the Brigham and Women's Hospital. Daniela was part of the team that identified the extracellular calcium-sensing receptor, CaR, which is the first G protein-coupled receptor hah has an ion, calcium, as its ligand. She then went on to identify the renal calcium-sensing receptor. Following her work on the CaR, Daniela was awarded the first prize in Excellence in Research from the American Society of Nephrology and National Kidney Foundation, a Research Fellowship from the National Kidney Foundation and The Wellcome Trust Prize for Excellence in Physiology. In 1997, Daniela moved to the UK and established her own research group at Manchester University, remaining there until 2004. In 2004, she moved to the School of Biosciences at Cardiff University where currently she is Professor of Physiology and Deputy Head of the School of Biosciences. Daniela’s research interests centre on how cells sense and respond to perturbations in the extracellular milieu, particularly Ca2+, polycations and nutrients. Daniela’s scientific goals are: 1. to develop CaSR antagonists (calcilytics) as novel therapeutics for inflammatory lung disease, and; 2. to define the role of the CaSR in blood pressure control and in the prevention of vascular calcification.

David Leather

Medical Vice President, Respiratory Franchise, GSK

Dave Leather is a Global Medical Affairs Leader in the Respiratory Franchise at GSK, based at GSK House in London in the UK. He leads the Global Medical Expert team: a team of world renowned Respiratory experts who work for GSK providing internal scientific and clinical expertise to support promoted medicines and those in development. For the last 3 years he led a team responsible for developing phase lll and phase lV trials for respiratory medicines. He also has a leadership role in “real world pragmatic trials” and is the Franchise leader of the internationally recognised Salford Lung Study.
Dave joined GSK in 2000 and has held a variety of posts within the company. Originally a primary care physician in Bolton with an interest in respiratory disease, Dave managed asthma and COPD clinics in a primary care setting and held a post as a clinical assistant in Respiratory Medicine at University Hospital Aintree in Liverpool. He was a GP Course Organiser, a member of the Council of the Royal College of GPs (RCGP), and worked as a media doctor for the BBC and commercial radio.

Donna Finch

Principal Scientist, MedImmune

I am currently Principal Scientist and Team Leader in Respiratory, Inflammation and Autoimmunity (RIA) at MedImmune Ltd, Cambridge, UK, having joined 18 years ago when Cambridge Antibody Technology.
My team is currently focussed on investigating novel mechanisms and target generation in the pathogenesis of COPD (chronic obstructive pulmonary disease). We focus on human biology, accessing valuable disease lung samples, and using innovative 3D-culture techniques, imaging and –omics technologies. Along with RIA and Translational Science colleagues at our Gaithersburg site, we address patient stratification in COPD, and we are particularly interested in biomarkers and epidemiology of exacerbations of COPD. I have been involved in multiple drug projects in COPD and inflammatory diseases (such as rheumatologic disease), leading several biologic therapies through to early clinical trials (such as antibodies to interleukin 6, interleukin-1RI, and others). I am an Industrial Lead for the UK Consortium COPD-MAP, and we work directly with Spiromics and COPD-GENE investigators (US consortia), and collaborate extensively with key COPD investigators worldwide.
I have previously worked for Glaxo Group Research (UK), and Roche Biosciences (Palo Alto, Ca, USA), and I achieved my BSc from University of Bristol, and my PhD from University of Leicester, where I studied the signalling and function of muscarinic receptors in smooth muscle.

Ewan Walters

Senior Director Medical Affairs UK & Ireland , Teva UK Ltd

Matthew Thomas

Principle Scientist , AstraZeneca

Monica Fletcher

Chief Executive Officer, Education for Health

Monica Fletcher is Chief Executive of Education for Health. She is also Chair of UK Inhaler Group, Knowledge Exchange Lead for Asthma UK Centre for Applied Research (AUKCAR) and Past Chair of the European Lung Foundation

Monica influences national and international policies through activities including membership of the WHO’s Global Alliance Against Respiratory Disease, European Respiratory Society, American Thoracic Society, European COPD Coalition, and International Primary Care Respiratory Group.

Monica is honoured with an OBE, a Queen’s Nursing Institute Fellowship and a European Respiratory Society Fellowship, joining a group of leaders acknowledged for lifetime excellence and contributions to respiratory medicine.

Neelima Khairatkar Joshi

Dr. Neelima Khairatkar-Joshi is a Sr. Vice President & Head, NCE Drug Discovery Research at Glenmark Pharmaceuticals, New Mumbai, India. She has over 24 years of experience in the New Drug Discovery research.

In her current role, she is responsible for driving all preclinical decisions leading to identification of an IND enabling lead candidate in therapy areas of Inflammation, Chronic Pain and Respiratory Disease. During her 16 years career at Glenmark, she has successfully contributed to deliver numerous IND enabling innovative molecules that progressed into clinical trials. Dr. Neelima is an inventor on over 80 published patents (world), has authored over 50 abstracts and 10 peer reviewed publications / book chapters of renowned publishers / journals such as Elsevier, Expert Opinion, Trend and Molecular Medicine. She has presented over 15 invited lectures in key international forums in areas of drug discovery.

Prior to joining Glenmark, Dr Neelima worked on natural product based New Drug Discovery Research at Hoechst Marion Roussel (Now Sanofi Avantis) for about 8 years. She earned her Ph.D. in Molecular Biology, Masters in Microbiology.

Neil Barnes

Medical Head Global Respiratory Franchise, GSK

Quan Yang

Pharmaceutical Assessor, MHRA

Dr Yang is a Pharmaceutical Assessor at the Medicines and Healthcare Products Regulatory Agency (MHRA) in London. She is responsible for assessing the chemical and pharmaceutical data in relation to abridged applications (national, mutual recognition, decentralised and centralised) and new applications of topical products including inhaled products, dermatological products and endocrine systems. Dr Yang has been involved in the assessment of applications for new inhaled products, including dry powder inhalers and MDI’s, and the provision of Scientific Advices for both national and European centralised procedures. Dr Yang is a UK registered pharmacist and holds a PhD in pharmaceutical science.

Stefan Leiner

Chemical-Pharmaceutical Expert, Boehringer Ingelheim

Dr. Stefan Leiner is a pharmacist by training and joined Boehringer Ingelheim in Germany in 1987. After a couple of years in manufacture, galenical and analytical development, he focussed on inhalation forms.

He now holds the title of a “CMC Expert", meaning he is responsible for the scientific standard of the Module 3 of MAAs. He wrote the Quality Overall Summaries for many of Boehringer Ingelheim’s new inhalation developments.

Stefan Leiner represents Boehringer Ingelheim in the International Pharmaceutical Aerosol Consortium - Regulation and Science (IPAC-RS) and was chair of this organization. He participated in the development of the ISO 20072 Standard on "Aerosol Drug Delivery Devices". He is active in the German Pharmacopeia.

Stephen Beckman

Head of Global Respiratory and Allergy, Mylan Pharmaceuticals

Stephen Beckman has devoted his entire 24-year career to the life sciences industry in a broad range of operational and commercial positions within both regional (US) and global organizations. During his career, Stephen has become an expert in a number of therapeutic areas including respiratory and rare diseases as well as specific subject matter areas in commercial operations, start-up management, strategic planning, business development, product launch, and partnership management. He is currently Head of Global Respiratory and Allergy at Mylan, Inc. In this role he is responsible for the global strategy and implementation of the respiratory and allergy portfolio which is expected to exceed $2 billion by 2018. Previously, Mr Beckman was the President/Director of North America for Pharmaxis, Inc. with responsibility over all business activities for both North and South America. Mr. Beckman lead the efforts for the US approval of Aridol®, a novel new asthma diagnostic and the approval efforts for Bronchitol® for the treatments of cystic fibrosis and bronchiectasis.
Stephen has demonstrated a consistent ability to effectively work within emerging pharmaceutical companies such as Pharmaxis as General Manager of Exaeris, Inc. as well as successful track records in a number of large pharmaceutical concerns as Corporate Vice President of Global Marketing at Altana Pharmaceuticals and Worldwide Director of Pulmonary at SmithKline Beecham Pharmaceuticals (GSK). It has been through these diverse experiences that Mr. Beckman has been able to develop critical skill sets such as entrepreneurial ingenuity, transparent leadership, strategic communication, and critical thinking required to deliver sustainable solutions within the ever-changing landscape of the Pharmaceutical Industry.
The pathway to these positions has been built from a career in sales and product management, licensing, and portfolio development with Astra Zeneca, and Fisons Pharmaceuticals.
Stephen earned his B.S., in business from Syracuse University with an additional concentration in Advertising and Communications. He actively participates in the life sciences community through a number of industry boards, committees and lecturing which include:
• University of Pennsylvania (Wharton) Executive MBA – annual guest lecturer on business strategy and human capital.
• Adjunct lecturer at St. Joseph’s University Pharmaceutical Executive MBA.
• Committee member Genesyn IP Ventures in association with Temple University School of Medicine and health system.

Wisia Wedzicha

Professor of Respiratory Medicine , Imperial College London

Sponsors and Exhibitors

View detailsNemeraSponsors and Exhibitorshttp://www.nemera.net/Nemera is a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology & generics industries, with a long-standing expertise in inhalation devices.
Nemera’s expertise covers five delivery routes: Pulmonary, Ophthalmic, Nasal/Auccal/Auricular, Dermal/Transdermal, Parenteral.
Nemera always puts patients first, providing the most comprehensive range of devices in the industry, including off-the-shelf innovative systems, customized design development and contract manufacturing.

View detailsVitalographSponsors and Exhibitorshttp://www.vitalograph.co.uk/clinical-trials/Vitalograph are a market leader in the delivery of standardized equipment and centralized cardio-respiratory data capture services and patient reported outcomes for clinical trials. When you choose Vitalograph as your clinical trial partner you can be confident that we have the experience to understand your requirements and the expertise to make them happen.

Official Media Partner

View detailsONdrugDelivery MagazineOfficial Media Partnerhttp://ondrugdelivery.comONdrugDelivery Magazine is the highly regarded, world-leading series of sponsored themed drug delivery publications. Uniquely, each issue focuses tightly on one topic within the field of drug delivery. With a truly global readership already in excess of 40,000, and with contributions and loyal support from many of the most important companies in the drug delivery business - from among the largest to the smallest - ONdrugDelivery Magazine is a must for those in the industry who need to know what's going on in drug delivery.

Official Publication

View detailsInt. J. of Immunological StudiesOfficial Publicationhttp://www.inderscience.com/ijisIJIS publishes a broad range of papers on all aspects of immunology from scientists in academic and non-academic organisations as well as business and government worldwide. IJIS is the flagship journal of the Frontiers in Immunology Research Network.

View detailsInternational Journal of Biomedical Engineering and TechnologyOfficial Publicationhttp://www.inderscience.com/ijbetIJBET addresses cutting-edge research in the multi-disciplinary area of biomedical engineering and technology. Medical science incorporates scientific/technological advances combining to produce more accurate diagnoses, effective treatments with fewer side effects, and improved ability to prevent disease and provide superior-quality healthcare. A key field here is biomedical engineering/technology, offering a synthesis of physical, chemical, mathematical and computational sciences combined with engineering principles to enhance R&D in biology, medicine, behaviour, and health. IJBET includes the Asia-Pacific Chapter in Biomedical Wireless Technology (APC-BWT).

View detailsInternational Journal of BiotechnologyOfficial Publicationhttp://www.inderscience.com/ijbtIJBT provides an international forum and refereed authoritative source of information in the field of Biotechnology and Biotechnics, with emphasis on management and economics, as well as the political and social issues. It aims to disseminate knowledge, provide a learned reference in the field, and establish channels of communication between academic and research experts, policy makers and executives in industry, commerce and investment institutions.

View detailsInternational Journal of Healthcare Technology and ManagementOfficial Publicationhttp://www.inderscience.com/ijhtmIJHTM is a series emerging from the International Journal of Technology Management. It provides an international forum and refereed authoritative sources of information in the fields of the economics and management of technology in healthcare.

View detailsInternational Journal of Medical Engineering and InformaticsOfficial Publicationhttp://www.inderscience.com/ijmeiIJMEI promotes an understanding of the structural/functional aspects of disease mechanisms and the application of technology towards the treatment/management of such diseases. It seeks to promote interdisciplinary collaboration between those interested in the theoretical and clinical aspects of medicine and to foster the application of computers and mathematics to problems arising from medical sciences. IJMEI includes authoritative review papers, the reporting of original research, and evaluation reports of new/existing techniques and devices. Each issue also contains a comprehensive information service.

View detailsInternational Journal of Technology, Policy and ManagementOfficial Publicationhttp://www.inderscience.com/ijtpmIJTPM is a refereed international journal that provides a professional and scholarly forum in the emerging field of decision making and problem solving in the integrated area of technology policy and management at the operational, organisational and public policy levels.

Supporters

View detailsAbsaveSupportershttp://www.absave.comAbsave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!

View detailsBioChem Adda Supportershttps://www.biochemadda.com/BioChem Adda is a Not-just-for-Profit organization which aims to bring out the most reliable and transparent information about everything related to jobs, careers, education, news, articles, and events from the field of BioSciences and Chemistry!

View detailsBioPharm InsightSupportershttp://www.biopharminsight.com
BioPharm Insight is your definitive guide to the global life sciences community. Subscribers take action on forward-looking intelligence uncovered by an independent team of investigative journalists, and make strategic business decisions using the most comprehensive and powerful real-time database of market analytics and key contacts. Featuring an intuitive online interface and exclusive Active IntelT relational content technology, BioPharm Insight provides an unrivaled capability to segment and analyze the industry with detailed and searchable profiles.

View detailsBiosaveSupportershttp://www.Biosave.comBiosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.

View detailsContract BiotechnologySupportershttp://www.contract-biotechnology.comContract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. We are an online R&D matching tool that connects Scientifics and organizations involved in discovery, development and delivery of new healthcare products with service and products providers worldwide. Life science information technology is undergoing a revolution. Part of that revolution involves new, unexplored business models, open innovation, open data and collaboration. If you have a project or idea that you would like to propose, develop or run, we can help. A New Collaboration Network Model for Discovery Research and Development • Effective Platform: the 95% • 5.000 registered users // > 15.000 Newsletter subscribers • Geographical background: 45,5% Europe / 37,5% North America / 16,5% Asia / 0,5% ROW • Professional background: Outsourcing Manager, Project Manager, CEO, Business Developer, CSO, Account Manager, Sales & Marketing People, Scientists, R&D. For further information, please visit our website www.contract-biotechnology.com

View detailsCrowd ReviewsSupportershttps://www.crowdreviews.com/best-investment-management-softwareCrowdReviews.com is a transparent online platform for determining which products and services are the best based on the opinion of the crowd. The crowd consists of Internet users which have experienced products and services first-hand and have an interest in letting other potential buyers their thoughts on their experience.

View detailsDrug Development TechnologySupportershttp://www.drugdevelopment-technology.comDrugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval.
Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.

View detailsDrug Discovery TodaySupportershttp://www.drugdiscoverytoday.com/Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.

View detailsFarmavitaSupportershttp://www.farmavita.net/Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.

View detailsGate2BiotechSupportershttp://www.gate2biotech.comGate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.

View detailsInternational Pharmaceutical IndustrySupportershttp://www.ipimediaworld.com IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.

View detailsLabsaveSupportershttp://www.labsave.comLabsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/

View detailsMednousSupportershttp://www.MedNous.comMedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com

View detailsPharmaceutical Manufacturing and Packing Sourcer (PMPS)Supportershttp://www.samedanltd.com/magazine/15Pharmaceutical Manufacturing and Packing Sourcer (PMPS) is a specialist magazine for the pharmaceutical manufacturing, packaging and supply chain sectors. Every quarterly edition features articles written by key opinion leaders, ranging from pharmaceutical sponsors and key services providers, to industry associations and regulatory authorities. PMPS combines technological, operational and corporate perspectives on this growing sector, along with industry interviews, event previews and book reviews.
Now you can also read PMPS on the go with the new Samedan app. Click here to download it now for your iPhone or iPad: http://bit.ly/IJECug

View detailsPharmaceutical TechnologySupportershttp://www.pharmaceutical-technology.comPharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.

View detailsPharmaceutical-ReviewSupportershttp://www.pharmaceutical-review.comPharmaceutical-review.com is part of Integrated IQ technologies Private Limited(IIQ). A Leading platform for all the Pharma manufacturing companies and buyers across the world.Having a subscriber database of more than 120,000 globally helping the clients to reach their target buyers through our exclusive listing, branding(banner advertisement), e-news letters, e-mail marketing, product reviews, product launch promotions, event marketing, search engine marketing and social media marketing services.

View detailsPharmacircleSupportershttp://www.pharmacircle.comPharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….

View detailsPharmalicensingSupportershttp://www.pharmalicensing.comPharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide.
Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world.
Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.

View detailsPharmavisionSupportershttp://www.pharmavision.co.ukPharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.

View detailsSelect ScienceSupportershttp://www.selectscience.net/SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.

View detailsSwiss Biotech AssociationSupportershttp://www.swissbiotech.org/The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.

View detailsTechnology NetworksSupportershttp://go.technologynetworks.com/subscribe-to-newslettersFounded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com

View detailsThiemeSupportershttp://www.thieme.com/ Thieme is an award-winning international medical and science publisher promoting the latest research findings in its books, journals, and electronic products. Seminars in Respiratory and Critical Care Medicine is a topic-driven review journal providing comprehensive coverage of respiratory and pulmonary disorders. The journal includes new diagnostic and therapeutic procedures, genetic breakthroughs and clinical management as related to such areas as lung or pleural diseases, cystic fibrosis and many other related disorders. Link to the journal: https://www.thieme.de/de/seminars-respiratory-critical-care-medicine/journal-information-9821.htm

Asthma & COPD 2015-2016 Delegate List

Sponsors and Exhibitors

Nemera

Nemera is a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology & generics industries, with a long-standing expertise in inhalation devices.
Nemera’s expertise covers five delivery routes: Pulmonary, Ophthalmic, Nasal/Auccal/Auricular, Dermal/Transdermal, Parenteral.
Nemera always puts patients first, providing the most comprehensive range of devices in the industry, including off-the-shelf innovative systems, customized design development and contract manufacturing.

Vitalograph

Vitalograph are a market leader in the delivery of standardized equipment and centralized cardio-respiratory data capture services and patient reported outcomes for clinical trials. When you choose Vitalograph as your clinical trial partner you can be confident that we have the experience to understand your requirements and the expertise to make them happen.

Media Partners

ONdrugDelivery Magazine

ONdrugDelivery Magazine is the highly regarded, world-leading series of sponsored themed drug delivery publications. Uniquely, each issue focuses tightly on one topic within the field of drug delivery. With a truly global readership already in excess of 40,000, and with contributions and loyal support from many of the most important companies in the drug delivery business - from among the largest to the smallest - ONdrugDelivery Magazine is a must for those in the industry who need to know what's going on in drug delivery.

Media Partners

International Journal of Medical Engineering and Informatics

IJMEI promotes an understanding of the structural/functional aspects of disease mechanisms and the application of technology towards the treatment/management of such diseases. It seeks to promote interdisciplinary collaboration between those interested in the theoretical and clinical aspects of medicine and to foster the application of computers and mathematics to problems arising from medical sciences. IJMEI includes authoritative review papers, the reporting of original research, and evaluation reports of new/existing techniques and devices. Each issue also contains a comprehensive information service.

International Journal of Healthcare Technology and Management

IJHTM is a series emerging from the International Journal of Technology Management. It provides an international forum and refereed authoritative sources of information in the fields of the economics and management of technology in healthcare.

Int. J. of Immunological Studies

IJIS publishes a broad range of papers on all aspects of immunology from scientists in academic and non-academic organisations as well as business and government worldwide. IJIS is the flagship journal of the Frontiers in Immunology Research Network.

International Journal of Biotechnology

IJBT provides an international forum and refereed authoritative source of information in the field of Biotechnology and Biotechnics, with emphasis on management and economics, as well as the political and social issues. It aims to disseminate knowledge, provide a learned reference in the field, and establish channels of communication between academic and research experts, policy makers and executives in industry, commerce and investment institutions.

International Journal of Technology, Policy and Management

IJTPM is a refereed international journal that provides a professional and scholarly forum in the emerging field of decision making and problem solving in the integrated area of technology policy and management at the operational, organisational and public policy levels.

International Journal of Biomedical Engineering and Technology

IJBET addresses cutting-edge research in the multi-disciplinary area of biomedical engineering and technology. Medical science incorporates scientific/technological advances combining to produce more accurate diagnoses, effective treatments with fewer side effects, and improved ability to prevent disease and provide superior-quality healthcare. A key field here is biomedical engineering/technology, offering a synthesis of physical, chemical, mathematical and computational sciences combined with engineering principles to enhance R&D in biology, medicine, behaviour, and health. IJBET includes the Asia-Pacific Chapter in Biomedical Wireless Technology (APC-BWT).

Media Partners

Contract Biotechnology

Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. We are an online R&D matching tool that connects Scientifics and organizations involved in discovery, development and delivery of new healthcare products with service and products providers worldwide. Life science information technology is undergoing a revolution. Part of that revolution involves new, unexplored business models, open innovation, open data and collaboration. If you have a project or idea that you would like to propose, develop or run, we can help. A New Collaboration Network Model for Discovery Research and Development • Effective Platform: the 95% • 5.000 registered users // > 15.000 Newsletter subscribers • Geographical background: 45,5% Europe / 37,5% North America / 16,5% Asia / 0,5% ROW • Professional background: Outsourcing Manager, Project Manager, CEO, Business Developer, CSO, Account Manager, Sales & Marketing People, Scientists, R&D. For further information, please visit our website www.contract-biotechnology.com

Swiss Biotech Association

The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.

Drug Development Technology

Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval.
Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.

Select Science

SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.

Biosave

Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.

BioPharm Insight

BioPharm Insight is your definitive guide to the global life sciences community. Subscribers take action on forward-looking intelligence uncovered by an independent team of investigative journalists, and make strategic business decisions using the most comprehensive and powerful real-time database of market analytics and key contacts. Featuring an intuitive online interface and exclusive Active IntelT relational content technology, BioPharm Insight provides an unrivaled capability to segment and analyze the industry with detailed and searchable profiles.

Pharmaceutical Manufacturing and Packing Sourcer (PMPS)

Pharmaceutical Manufacturing and Packing Sourcer (PMPS) is a specialist magazine for the pharmaceutical manufacturing, packaging and supply chain sectors. Every quarterly edition features articles written by key opinion leaders, ranging from pharmaceutical sponsors and key services providers, to industry associations and regulatory authorities. PMPS combines technological, operational and corporate perspectives on this growing sector, along with industry interviews, event previews and book reviews.
Now you can also read PMPS on the go with the new Samedan app. Click here to download it now for your iPhone or iPad: http://bit.ly/IJECug

Pharmalicensing

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide.
Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world.
Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.

International Pharmaceutical Industry

IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.

Crowd Reviews

CrowdReviews.com is a transparent online platform for determining which products and services are the best based on the opinion of the crowd. The crowd consists of Internet users which have experienced products and services first-hand and have an interest in letting other potential buyers their thoughts on their experience.

Labhoo

Technology Networks

Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com

Pharmaceutical-Review

Pharmaceutical-review.com is part of Integrated IQ technologies Private Limited(IIQ). A Leading platform for all the Pharma manufacturing companies and buyers across the world.Having a subscriber database of more than 120,000 globally helping the clients to reach their target buyers through our exclusive listing, branding(banner advertisement), e-news letters, e-mail marketing, product reviews, product launch promotions, event marketing, search engine marketing and social media marketing services.

Farmavita

Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.

Mednous

MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com

Thieme

Thieme is an award-winning international medical and science publisher promoting the latest research findings in its books, journals, and electronic products. Seminars in Respiratory and Critical Care Medicine is a topic-driven review journal providing comprehensive coverage of respiratory and pulmonary disorders. The journal includes new diagnostic and therapeutic procedures, genetic breakthroughs and clinical management as related to such areas as lung or pleural diseases, cystic fibrosis and many other related disorders. Link to the journal: https://www.thieme.de/de/seminars-respiratory-critical-care-medicine/journal-information-9821.htm

Pharmaceutical Technology

Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.

Drug Discovery Today

Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.

Gate2Biotech

Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.

BioChem Adda

BioChem Adda is a Not-just-for-Profit organization which aims to bring out the most reliable and transparent information about everything related to jobs, careers, education, news, articles, and events from the field of BioSciences and Chemistry!

Labsave

Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/

Holiday Inn Kensington Forum

97 Cromwell Road
London SW7 4DN
United Kingdom

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington.

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow.

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel.

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event.

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee.

Cookie Policy

From May 2011 a new privacy law came into effect across the EU. The law requires
that websites ask visitors for consent to use most web cookies. We use cookies to
ensure you get the best experience on our website –Tick here to accept cookie use
Details of our cookie use may be found here.

WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy,
which maintains that in order to be effective, learning should be organised and
structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional
competence’

CPD is a common requirement of individual membership with professional bodies and
Institutes. Increasingly, employers also expect their staff to undertake regular
CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do
not become obsolete, and allows for best practice and professional standards to
be upheld.

CPD can be undertaken through a variety of learning activities including instructor
led training courses, seminars and conferences, e:learning modules or structured
reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with
a collective membership of circa 4 million professionals, and they all expect their
members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked
to a licence to practice, for others it’s obligatory. By ensuring that their members
undertake CPD, the professional bodies seek to ensure that professional standards,
legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide
online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’
or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve
within a given time period. These schemes can also use different ‘currencies’ such
as points, merits, units or credits, where an individual must accumulate the number
required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of
learning.

‘Output’ based schemes are learner centred. They require individuals to set learning
goals that align to professional competencies, or personal development objectives.
These schemes also list different ways to achieve the learning goals e.g. training
courses, seminars or e:learning, which enables an individual to complete their CPD
through their preferred mode of learning.

As a formal provider of CPD certified activities, SMI Group can provide an indication
of the learning benefit gained and the typical completion. However, it is ultimately
the responsibility of the delegate to evaluate their learning, and record it correctly
in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces
and looking to the UK to benchmark educational standards. The undertaking of CPD
is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk